The objective of the study was to characterize at species level by phenotypic and different molecular methods the strains of Lactobacillus spp. used as constituents of five oral and four vaginal products. Susceptibilities to representative antibiotics were evaluated. In addition, total viable counts at mid and 3 months to deadline of shelf life, in the different formulations and the presence of eventual contaminant microorganisms were investigated.In all oral products the molecular characterization at species level of the strains of Lactobacillus spp. confirmed the strains stated on the label, except for one strain cited on the label as Lactobacillus casei, that our study characterized as Lactobacillus paracasei. In oral products total viable cell content complied with content claimed on the label. In three out four vaginal products (one product claimed "bacillo di Döderlein"), molecular characterization complied with the bacterial name stated on the label. Two vaginal products reported viable counts on the label that were confirmed by our study. The other vaginal products, which did not report bacterial counts on the label, showed a similar decrease of viable counts at different dates to deadline compared to the others. From all the tested products, contaminant microorganisms and acquired resistance to representative antibiotics by the probiotic strains were not detected.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5806746 | PMC |
http://dx.doi.org/10.1177/0394632015600534 | DOI Listing |
Curr Microbiol
January 2025
Department of Microbiology and Immunology, School of Medicine, Soonchunhyang University, Cheonan-si, Chungnam, 31151, Republic of Korea.
Lactic acid bacteria (LAB), traditionally consumed as fermented foods, are now being applied to the medical field beyond health-functional food as probiotics. Therefore, it is necessary to continuously discover and evaluate new strains with suitable probiotic characteristics, mainly focusing on safety. In this study, we isolated eight new strains from postmenopausal vaginal fluid using culturomics approaches, an emerging area of interest.
View Article and Find Full Text PDFInt J Pharm
January 2025
Department of Industrial Pharmacy, College of Pharmaceutical Sciences and Drug Manufacturing, Misr University for Science and Technology, Giza, Egypt. Electronic address:
Clotrimazole (CLO) is a strong antifungal drug approved to treat vaginal candidiasis (VC). Nanosponges (NSs) were developed to maintain providing CLO in a steady pattern with amplified accumulation in the vaginal mucosa. The quasi-emulsion solvent diffusion method was utilized to prepare NSs.
View Article and Find Full Text PDFBackground: Alzheimer's affects women 2:1 compared to men, suggesting sex-specific factors driving risk. Menopause, a female-specific phenomenon, induces a multi-system response across endocrine, metabolic, and immune-inflammatory systems. Despite known effects on these systems, the impact on the brain and AD risk remains incompletely understood, limiting preventative options.
View Article and Find Full Text PDFMenopause
January 2025
Cosette Pharmaceuticals, Inc, Bridgewater, NJ.
Objective: The aims of this study were to assess the prevalence of urinary tract infections (UTI) in women newly diagnosed with vulvovaginal atrophy (VVA) versus women without VVA and to evaluate the potential of vaginal prasterone to be used in postmenopausal VVA women with UTI as prophylaxis to reduce the future UTI risk. As a first subgroup analysis, women using aromatase inhibitors, medications that stop the production of estrogen were analyzed. As a second subgroup analysis, we looked at women with diabetes to investigate whether the same prophylaxis approach should be considered.
View Article and Find Full Text PDFNutrients
December 2024
Department of Obstetrics and Gynecology, Emek Medical Center, Afula 1834111, Israel.
Background/objective: This study aimed to investigate the efficacy of oral probiotic supplementation in preventing vulvovaginal infections (VVIs) in pregnant women, specifically focusing on abnormal vaginal flora (AVF), bacterial vaginosis (BV), and vulvovaginal candidiasis (VVC).
Methods: A multicenter-prospective-randomized, double-blind, placebo-controlled trial was conducted during 2016-2019. Women with normal vaginal flora (Nugent score < 4 and no candida) were divided into a research group, receiving 2 capsules/day of oral probiotic formula containing , , , , , and , or a control group, receiving a placebo until delivery.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!